There is good news for those impacted by the effects of Diabetes. Recent reports have been favorable for the use of Lucentis Injections to treat a complication of Diabetic Retinopathy called diabetic Macular Edema (DME) a cause of significant vision loss in patients with diabetes. Patients with Diabetic Retinopathy in the form of DME who received the drug experienced rapid and sustained improvement in vision compared to those who received a placebo injection.
Diabetic Macular Edema or DME is the swelling of retina in people with diabetic eye disease called Diabetic Retinopathy, which causes damage to the blood vessels of retina. The DME patients suffers fluid leak from the damaged blood vessel to the central portion of retina, causing it to swell leading to blurred vision, severe vision loss and blindness.
Of the 26 million U.S. people with diabetes, a portion of up to 10 percent tends to develop DME during their lifetime, and up to 75,000 new cases of DME are estimated to develop each year. Currently, DME patients are treated with laser surgery that helps seal the leaky blood vessels to slow the leakage of fluid and reduce the amount of fluid in the retina.
Lucentis is approved for use by the U.S. Food & Drug Administration (FDA) for the treatment of “Wet” Age-Related Macular Degeneration (AMD) and for Macular Edema following Retinal Vein Occlusion. In 2011, Lucentis was approved for treatment of visual impairment due to DME in Europe.
The key to successful treatment of Diabetic Retinopathy is early detection and intervention. If you or someone you know has diabetes or is even prediabetic please feel free to schedule a Diabetic Eye Examination Alabama Eye & Cataract Center by phoning 205.930.0930.
Bladeless All Laser LASIK at Michelson Laser Vision, Birmingham - Laser Cataract Surgery & Lens Implants at Alabama Eye & Cataract Center, Birmingham.
